New SNP Discovery Brings Decode Closer to Developing Multi-Gene Panel Test in Urinary Bladder Cancer | GenomeWeb

Originally published April 6.

By Turna Ray

Researchers from Decode Genetics and Radbound University Nijmegen Medical Center have discovered a SNP that both confers hereditary risk of urinary bladder cancer and is associated with somatic mutations linked to the growth of low-grade tumors. The discovery of this SNP "appears to bridge the divide" between germline and somatic mutations in UBC, according to the researchers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.